GENERIC NAME: ombitasvir, paritaprevir and ritonavir
BRAND NAME: Technivie
DRUG CLASS AND MECHANISM: Technivie is a combination oral medication containing ombitasvir, paritaprevir, and ritonavir. Technivie is used with ribavirin (Rebetol) to treat genotype 4 hepatitis C virus (HCV) infections in patients without liver cirrhosis. Technivie belongs to a class of drugs called direct-acting antiviral agents. Similar drugs include
- boceprevir (Victrelis),
- sofosbuvir (Sovaldi),
- simeprevir (Olysio),
- telaprevir (Incivek), and
- ombitasvir, paritaprevir, ritonavir, and dasabuvir (Viekira Pak).
Ombitasvir and paritaprevir are antivirals that have direct activity against HCV. They block the effect of proteases which are enzymes that HCV uses for making new viruses, leading to reduced numbers of HCV copies in the body. Ombitasvir blocks HCV NS5A protease while paritaprevir blocks HCV NS3/4A protease. The third medicine in Technivie, ritonavir, is not active against the HCV virus. It is used to increase blood levels of paritaprevir by inhibiting the breakdown of paritaprevir.
The combination of Technivie and ribavirin for 12 weeks resulted in 100% cure rates in patients with genotype 4 chronic HCV without cirrhosis. Cure was defined as undetectable levels of HCV in the body 3 months after treatment had ended. The FDA approved Technivie in July 2015.
PRESCRIBED FOR: Technivie is used in combination with ribavirin to treat adults with chronic HCV genotype 4 infection who have not developed cirrhosis.
Quick GuideHepatitis C (Hep C) Symptoms and Treatment
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.